Research ArticleSpecial Communications

Fluid Matters in Choosing Antihypertensive Therapy: A Hypothesis That the Data Speak Volumes

Robert P. Blankfield
The Journal of the American Board of Family Practice March 2005, 18 (2) 113-124; DOI: https://doi.org/10.3122/jabfm.18.2.113

References

  1. ↵
    Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 20009; 356: 1949–54.
  2. ↵
    Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356: 1955–64.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–75. Erratum in: JAMA 2002;288:2976.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97. Erratum in: JAMA 2003;289:178 and JAMA 2004;291:2196.
    OpenUrlCrossRefPubMedWeb of Science
  5. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–44.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72. Erratum in: JAMA 2003; 290:197.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Wing LM, Reid CM, Ryan P, et al; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–92.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.
    OpenUrlCrossRefPubMedWeb of Science
  9. Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667–76.
    OpenUrlCrossRefPubMedWeb of Science
  10. Black HR, Elliott WJ, Grandits G, Grambsch P, et al; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073–82.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151–8.
    OpenUrlPubMedWeb of Science
  14. ↵
    Weber M. The ALLHAT report: a case of information and misinformation. J Clin Hypertens 2003; 5: 9–13.
    OpenUrlCrossRef
  15. ↵
    de Leeuw PW, Birkenhäger WH. Effects of verapamil in hypertensive patients. Acta Med Scand 1984; 681 Suppl: 125–8.
    OpenUrl
  16. ↵
    Conlin PR, Williams GH. Use of calcium channel blockers in hypertension. Adv Intern Med 1998; 43: 533–62.
    OpenUrlPubMed
  17. ↵
    van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RAP, Huysmans TM. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J Hypertens 1996; 14: 1041–5.
    OpenUrlPubMed
  18. ↵
    Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol 1985; 249: F619–29.
  19. ↵
    Kaplan NM. Calcium entry blockers in the treatment of hypertension: current status and future prospects. JAMA 1989; 262: 817–23.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Epstein M, De Micheli AG. Natriuretic effects of calcium antagonists. In: Calcium antagonists in clinical medicine. Epstein M, editor. Philadelphia: Hanley and Belfus; 1992. p. 349–66.
  21. ↵
    Ene MD, Williamson PJ, Roberts CJC, Waddell G. The natriuresis following oral administration of the calcium antagonists-nifedipine and nitrendipine. Br J Clin Pharmacol 1985; 19: 423–7.
    OpenUrlPubMedWeb of Science
  22. ↵
    Ciccone M, Di Noia D, Di Michele L, Corriero F, Biasco, Rizzon P. Effects of lacidipine and nifedipine on the lower limb veins of nonphlebopathic patients. J Cardiovasc Pharmacol 1994; 23: S111–2.
  23. ↵
    Daniels AR, Opie LH. Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone. Am J Cardiol 1986; 57: 965–70.
    OpenUrlCrossRefPubMed
  24. ↵
    Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–5.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee. Br Med J (Clin Res Ed) 1988; 296: 468–72.
  26. ↵
    Fagan TC, Haggert BE, Liss C. Efficacy and tolerability of extended felodipine and extended-release nifedipine in patients with mild-to-moderate hypertension. Clin Ther 1994; 16: 634–46.
    OpenUrlPubMed
  27. ↵
    Steiner G, Pauly NC. Comparison of the efficacy and safety of trandolapril and nifedipine SR in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994; 4: S81–5.
    OpenUrl
  28. ↵
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72. Erratum in: Lancet 2000;356:514.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of low-dose combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86: 1182–7.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Koenig W. Efficacy and tolerability of felodipine and amlodipine in the treatment of mild to moderate hypertension: a randomized double blind multicentre trial. Drug Investig 1993; 5: 200–5.
    OpenUrl
  31. ↵
    Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995; 35: 1060–6.
    OpenUrlPubMedWeb of Science
  32. ↵
    Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996; 18: 1213–24.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341–6.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Kloner RA, Weinberger M, Pool JL, et al; Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol 2001; 87: 727–31.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    Freeling P, Davis RH, Goves JR, Burton RH, Orme-Smith EA. Control of hypertension in elderly patients with felodipine and metoprolol: a double-blind, placebo controlled clinical trial. Br J Clin Pharmacol 1987; 24: 459–64.
    OpenUrlCrossRefPubMed
  36. ↵
    Dahlöf B, Hosie J. Antihypertensive efficacy and tolerability of a fixed combination of metoprolol and felodipine in comparison with the individual substances in monotherapy. J Cardiovasc Pharmacol 1990; 16: 910–6.
    OpenUrlCrossRefPubMed
  37. ↵
    Hammond JJ, Cutler SA. A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician’s Study Group. Blood Press 1993; 2: 205–11.
    OpenUrlPubMed
  38. ↵
    Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension: Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997; 79: 431–5.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Scholze J, Bauer B, Massaro J. Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. Clin Exp Hypertens 1999; 21: 1447–62.
  40. ↵
    Eisner GM, Johnson BF, McMahon FG, et al. A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension. Am J Hypertens 1991; 4: 154S–157S.
    OpenUrlPubMed
  41. ↵
    Gradman AH, Frishman WH, Kaihlanen PM, Wong SC, Friday KJ. Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension. Am J Cardiol 1992; 70: 1571–5.
    OpenUrlCrossRefPubMed
  42. ↵
    Ruddy TD, Fodor JG. Nisoldipine CC and lisinopril alone or in combination for treatment of mild to moderate systemic hypertension. Cardiovasc Drugs Ther 1997; 11: 581–90.
    OpenUrlCrossRefPubMed
  43. ↵
    United Kingdom Lacidipine Study Group. A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. J Cardiovasc Pharmacol 1991; 17: S27–30.
  44. ↵
    Gennari C, Renato N, Pavese G, Gragnani S, Bianchini C, Buracchi P. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drugs Ther 1989; 3: 319–25.
  45. ↵
    Morgan TO, Anderson A, Cripps J, Adam W. The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol 1990; 38: S129–33.
  46. ↵
    Hosie J, Nasar MA, Belgrave GP, Walters EG. A comparative study of long acting diltiazem (tildiem LA) with sustained release nifedipine (nifedipine SR0 and bendrofluazide in the treatment of mild to moderate hypertension. Acta Cardiol 1994; 49: 251–65.
    OpenUrlPubMed
  47. ↵
    Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS): a randomized controlled trial. JAMA 1996; 276: 785–91.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    Pedrenelli R, Dell’Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens 2001; 15: 455–61.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    Iabichella ML, Dell’Omo G, Melillo E, Pedrinelli R. Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients. Hypertension 1997; 29: 751–6.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    White WB, Johnson MF, Anders RJ, Elliott WJ, Black HR. Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. Am Heart J 2001; 142: 1010–5.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    Speders S, Sosna J, Schumacher A, Pfennigsdorf G. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol 1989; 13: S47–9.
    OpenUrlCrossRef
  52. ↵
    Karlberg BE, Andrup M, Odén A, et al. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Swedish Tarka trialists. Blood Press 2000; 9: 140–5.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    Cubeddu LX, Aranda J, Singh B. A comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response. JAMA 1986; 256: 2214–21.
    OpenUrlCrossRefPubMedWeb of Science
  54. ↵
    Levine JH, Ferdinand KC, Cargo P, Laine H, Lefkowitz M. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995; 8: 494–9.
    OpenUrlCrossRefPubMedWeb of Science
  55. Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens 1997; 15: 1337–44.
    OpenUrl
  56. ↵
    Bakris G, Sica D, Ram V, Fagan T, Vaitkus PT, Anders RJ. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens 2002; 15: 53–7.
    OpenUrlCrossRefPubMedWeb of Science
  57. ↵
    Cushman WC, Cohen JD, Jones RP, Marbury TC, Rhoades RB, Smith LK. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 1998; 11: 23–30.
    OpenUrlCrossRefPubMedWeb of Science
  58. Pool PE, Massie BM, Venkataraman K, et al. Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo-controlled trial. Am J Cardiol 1986; 57: 212–7.
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    Hedner T, Thulin T, Gustafsson S, Olsson SO. A comparison of diltiazem and metoprolol in hypertension. Swedish Diltiazem-Metoprolol Multicentre Study Group. Eur J Clin Pharmacol 1990; 39: 427–33.
    OpenUrlPubMed
  60. ↵
    Weir MR, Josselson J, Giard MJ, et al. Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. Am J Cardiol 1987; 60: 36I–41I.
    OpenUrlPubMed
  61. Ruddy TD, Wright JM, Savard D, Handa SP, Chockalingam A, Boulet AP. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. Cardiovasc Drugs Ther 1995; 9: 413–20.
    OpenUrlCrossRefPubMedWeb of Science
  62. Nilsson P, Lindholm LH, Hedner T. The diltiazem different doses study—a dose-response study of once-daily diltiazem therapy for hypertension. J Cardiovasc Pharmacol 1996; 27: 469–75.
    OpenUrlPubMed
  63. ↵
    Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D. Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrochloride for the treatment of hypertension. Clin Ther 1992; 14: 148–57.
    OpenUrlPubMed
  64. ↵
    Warren JB, Dollery CT. The usefulness of alpha-adrenoceptor blockade in the treatment of hypertension. J Hypertens 1988; 6: S43–9.
    OpenUrlCrossRefWeb of Science
  65. ↵
    Bryson CL, Psaty BM. A review of the adverse effects of peripheral alpha-1 antagonists in hypertension therapy. Curr Control Trials Cardiovasc Med 2002; 3: 7.
  66. ↵
    Koshy MC, Mickley D, Bourgiognie J, Blaufox MD. Physiological evaluation of a new antihypertensive agent: prazosin HCl. Circulation 1977; 55: 533–7.
    OpenUrlAbstract/FREE Full Text
  67. McNair A, Rasmussen S, Nielsen PE, Rasmussen K. The antihypertensive effect of prazosin on mild to moderate hypertension, changes in plasma volume, extracellular volume and glomerular filtration rate. Acta Med Scand 1980; 207: 413–6.
    OpenUrlPubMed
  68. Bauer JH, Jones LB, Gaddy P. Effects of prazosin therapy on BP, renal function, and body fluid composition. Arch Intern Med 1984; 144: 1196–200.
    OpenUrlCrossRefPubMedWeb of Science
  69. Riegger GA, Haeske W, Kraus C, Kromer EP, Kochsiek K. Contribution of the renin-angiotensin system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment. Am J Cardiol 1987; 59: 906–10.
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    Goldberg MR, Sushak CS, Rockfold FW, Thompson WL. Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. Clin Pharmacol Ther 1988; 44: 78–92.
    OpenUrlPubMed
  71. ↵
    Torvik D, Madsbu H-P. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986; 21: S69–75.
  72. ↵
    Ott P, Storm TL, Krusell LR, Jensen H, Badskjaer J, Faergeman O. Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. Am J Cardiol 1987; 59: 73G–77G.
    OpenUrlPubMed
  73. ↵
    Carruthers G, Dessain P, Fodor G, Newman C, Palmer W, Sim D. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. Am J Cardiol 1993; 71: 575–81.
    OpenUrlCrossRefPubMed
  74. Krusell LR, Christensen CK, Pedersen OL. Alpha-adrenoreceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin. J Cardiovasc Pharmacol 1992; 20: 440–4.
    OpenUrlPubMed
  75. ↵
    Deger G. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. Am J Med 1986; 80: 62–7.
    OpenUrl
  76. Mersey JH. Long-term experience with terazosin for treatment of mild to moderate hypertension. Am J Med 1986; 80: 68–72.
    OpenUrlPubMed
  77. Sperzel WD, Glassman HN, Jordan DC, Luther RR. Overall safety of terazosin as an antihypertensive agent. Am J Med 1986; 80: 77–81.
    OpenUrl
  78. Luther RR, Glassman HN, Estep CB, Schmitz PJ, Horton JK, Jordan DC. Terazosin, a new selective alpha 1-adrenergic blocking agent: results of long-term treatment in patients with essential hypertension. Am J Hypertens 1988; 1: 237S–240S.
    OpenUrlPubMed
  79. ↵
    Ruoff G. Effect of withdrawal of terazosin therapy in patients with hypertension. Am J Med 1986; 80: 35–41.
    OpenUrl
  80. ↵
    Melkid A. Prazosin (‘Peripress’): a long-term study. Curr Med Res Opin 1984; 9: 219–28.
    OpenUrlPubMed
  81. ↵
    Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517–25.
    OpenUrlPubMedWeb of Science
  82. ↵
    Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertens 1979; 1: 274–80.
    OpenUrlFREE Full Text
  83. de Bruyn JHB, Man in’t Veld AJ, Wenting GJ, Derkx FH, Schalekamp MA. Haemodynamic profile of captopril treatment in various forms of hypertension. Eur J Clin Pharmacol 1981; 20: 163–8.
    OpenUrlPubMed
  84. ↵
    Andrén L, Karlberg BE, Svensson A, öhman P, Nilsson OR, Hansson L. Long-term effects of captopril and atenolol in essential hypertension. Acta Med Scand 1985; 217: 155–60.
    OpenUrlPubMed
  85. ↵
    Semplicini A, Rossi GP, Bongiovi S, et al. Time course of changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double-blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension. Clin Exp Pharmacol Physiol 1986; 13: 17–24.
    OpenUrlCrossRefPubMed
  86. ↵
    Tarazi RC, Bravo EL, Fouad RM, Omvik P, Cody RJ. Hemodynamic and volume changes associated with captopril. Hypertension 1980; 2: 576–85.
    OpenUrlFREE Full Text
  87. ↵
    Wenting GJ, DeBruyn JHB, Man in’T Veld AJ, et al. Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: correlations with short- and long-term effects on plasma renin. Am J Cardiol 1982; 49: 1453–9.
    OpenUrlPubMed
  88. ↵
    McLean D. Combination therapy with amlodipine and captopril for resistant systemic hypertension. Am J Cardiol 1994; 73: 55A–58A.
    OpenUrlPubMed
  89. ↵
    Helgeland A, Strømmen R, Hagelund CH, Tretli S. Enalapril, atenolol and hydrochlorazide in mild to moderate hypertension: a comparative multicentre study in general practice in Norway. Lancet 1986; 1: 872–5.
    OpenUrlPubMedWeb of Science
  90. ↵
    Comparison of monotherapy with enalapril and atenolol in mild to moderate hypertension. The Canadian Enalapril Study Group. CMAJ 1987; 137: 803–8.
    OpenUrlAbstract
  91. Rush JE, Lyle PA. Safety and tolerability of lisinopril in older hypertensive patients. Am J Med 1988; 85: S55–9.
    OpenUrl
  92. ↵
    Pittrow DB, Antlsperger A, Welzel D, Wambach G, Schardt W, Weidenger G. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. Cardiovasc Drugs Ther 1997; 11: 619–27.
    OpenUrlPubMed
  93. ↵
    Rosenthal J, Bahrmann H, Benkert K, et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker. Cardiology 1996; 87: 409–14.
    OpenUrlPubMed
  94. ↵
    Sierakowski B, Püchler K, Witte PU, Renneisen K, Delius W. Comparison of temocapril and atenolol in the long-term treatment of mild to moderate essential hypertension. Blood Press 1997; 6: 229–34.
    OpenUrlPubMed
  95. Bauer B, Lorenz H, Zahlten R. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1989; 13: S70–4.
  96. ↵
    Pedrenelli R, Dell’Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertens 2000; 35: 621–5.
    OpenUrlAbstract/FREE Full Text
  97. Guazzi MD, De Cesare N, Galli C, et al. Calcium-channel blockade with nifedipine and angiotensin converting enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation 1984; 70: 279–84.
    OpenUrlAbstract/FREE Full Text
  98. ↵
    Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14: 963–8.
    OpenUrlCrossRefPubMedWeb of Science
  99. ↵
    Zusman RM. Effects of converting enzyme inhibitors on the renin-angiotensin aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biological activity. Am J Kidney Dis 1987; 10 Suppl 1: 13–23.
    OpenUrl
  100. ↵
    Veelken R, Delles C, Hilgers KF, Schmieder RE. Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition. Am J Hypertens 2001; 14: 672–8.
    OpenUrlPubMed
  101. ↵
    Ruilope LM. Valsartan and the kidney: review of preclinical and clinical data. Adv Ther 2001; 18: 57–66.
    OpenUrlPubMed
  102. ↵
    Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87: 37–43.
    OpenUrlCrossRef
  103. ↵
    Oparil S, Williams D, Chrysant SG, Marbury T, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
    OpenUrlCrossRef
  104. ↵
    Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance survey on 12881 patients in England. J Hum Hypertens 2002; 16: 795–803.
    OpenUrlCrossRefPubMedWeb of Science
  105. ↵
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
    OpenUrlCrossRefPubMedWeb of Science
  106. ↵
    Freytag F, Schelling A, Meinicke T, Deichsel G. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001; 23: 108–23.
    OpenUrlCrossRefPubMedWeb of Science
  107. ↵
    Brogden RN, Heel RC, Speight TM, Avery GS. Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1977; 14: 321–48.
    OpenUrlPubMedWeb of Science
  108. Simpson WT. Nature and incidence of unwanted effects with atenolol. Postgrad Med J 1977; 53: S162–7.
    OpenUrl
  109. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997; 54: 161–85.
    OpenUrlPubMedWeb of Science
  110. ↵
    Lewis RV, Jackson PR, Ramsay LE. Side-effects of beta-blockers assessed using visual analogue scales. Eur J Clin Pharmacol 1985; 28: S93–6.
    OpenUrl
  111. ↵
    Ekbom T, Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester PO. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 1992; 10: 1525–30.
    OpenUrlPubMedWeb of Science
  112. ↵
    Materson BJ, Vlachakis ND, Glasser SP, et al. Influence of beta2 agonism and beta1 and beta2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol. Am J Cardiol 1989; 63: 58I–63I.
    OpenUrlCrossRefPubMed
  113. ↵
    Feliciano N, Kasarjian H, McMillen JI, et al. Safety and tolerability of metoprolol OROS in hypertension treatment. Am Heart J 1990; 120: 490–4.
    OpenUrlPubMed
  114. ↵
    LaPalio L, Schork P, Glasser S, Tifft C. Safety and efficacy of metoprolol in the treatment of hypertension in the elderly. J Am Geriatr Soc 1992; 40: 354–8.
    OpenUrlPubMed
  115. Frewin DB, Lloyd BL, Macdonald GJ, et al. A general-practice study of the efficacy and tolerability of metoprolol in mild essential hypertension. Med J Aust 1988; 148: 31–5.
    OpenUrlPubMed
  116. Foerster EC, Greminger P, Siegenthaler W, Vetter H, Vetter W. Atenolol versus pindolol: side-effects in hypertension. Eur J Clin Pharmacol 1985; 28: S89–91.
    OpenUrl
  117. ↵
    Streeten DH. Idiopathic edema. Pathogenesis, clinical features, and treatment. Endocrinol Metab Clin North Am 1995; 24: 531–47.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section